Crossing An Ethical Boundary
By Marcy Darnovsky,
The Journal of Life Sciences
| 05. 19. 2008
What prompted the recent headlines about genetically-modified human embryos? Why did a brief account of an experiment at Cornell University, presented last fall at an American Society for Reproductive Medicine conference and then published without fanfare in its journal Fertility and Sterility, suddenly make news around the world?
The work in question involved transferring a gene that codes for a fluorescing protein into a non-viable human embryo, and showing that all the cells in the embryo glowed after three days of cell division. As one of the research team's members later acknowledged, it was the first time that scientists are known to have created a genetically-modified human embryo.
Strangely, the study stayed beneath the public and media radar for months. It was brought to the attention of the UK's Sunday Times by Dr. David King, director of the British organization Human Genetics Alert, who came across it recently while reading a document prepared by the Human Fertilization and Embryology Authority. The story ran in the May 11 Sunday Times and was then picked up by the Associated Press and...
Related Articles
By Fyodor D. Urnov and Sadik H. Kassim, Nature | 04.21.2026
In February, the US Food and Drug Administration (FDA) proposed a radical rethink of how scientists, physicians and manufacturers develop personalized genetic therapies. The regulator’s suggested introduction of a ‘plausible mechanism pathway’ should increase incentives for drug companies to develop...
By Miguel Muñoz, Cadena SER | 08.04.2026
"Para ellos, una familia numerosa no solo es una preferencia personal, sino que es una obligación. Creen que tener tantos hijos como sea posible es necesario para evitar un futuro apocalíptico", aseguraba Xavier Orri, periodista y cofundador de Página Internacional...
By Ryan Knutson and Jessica Mendoza, The Journal. | 03.27.2026
Genetically engineered babies are banned in the U.S. But that isn’t stopping Silicon Valley tech titans from trying to make one. In this final installment from The Journal’s investigation into the fringes of the fertility industry, WSJ’s Emily Glazer reports...
By Antonio Regalado, MIT Technology Review | 03.30.2026
After operating in secrecy for years, a startup company called R3 Bio, in Richmond, California, suddenly shared details about its work last week—saying it had raised money to create nonsentient monkey “organ sacks” as an alternative to animal testing.
In...